Preventive Cardiology Digest

• CV safety confirmed: Met primary endpoint of noninferiority vs insulin glargine for MACE-4 (HR 0.84; 95% CI 0.59-1.20) in >2,700 high-risk T2D...

Prolonged sitting (>8 hours/day for 1 in 4 US adults) heightens cardiovascular disease risk.

• Just 20 minutes of daily activity slashes disease risk...

OCEANIC-STROKE Phase III highlights asundexian as promising for secondary prevention post-non-cardioembolic stroke/high-risk TIA:

• 26% reduction in...

Soluble fiber in oats (beta-glucans) binds LDL cholesterol and bile acids, with the liver pulling more LDL from blood to lower levels.

• Oats'...

Key findings from ACC Asia 2026 study on Korean adults with heart disease (2014–2023 data):

• Women show higher awareness and treatment rates for...

Oral GLP-1 orforglipron meets noninferior CV safety vs insulin glargine in T2D/obesity with elevated risk, with 16% lower MACE (HR 0.84)—huge for...

Practical update: Align moderate aerobic exercise (brisk walking/treadmill, 30 min, 5x/week) with patients' chronotype for superior CVD prevention.

-...

Tirzepatide CVOT Results

• 🔥 SURPASS-CVOT in NEJM: Tirzepatide was noninferior to dulaglutide with respect to major adverse cardiovascular events...

• Superior outcomes: Chronotype-aligned exercise lowered systolic BP by 10.8 mmHg (vs 5.5 mismatched), especially 13.6 mmHg in hypertensives; boosted...

• Noninferiority confirmed: Tirzepatide matched dulaglutide for MACE (CV death, MI, stroke) in T2D patients with ASCVD.
• Superior efficacy: Greater...

Cardiologists endorse oats as the standout complex carb for heart health:

• Rich in soluble fiber, binds cholesterol in the gut to lower LDL
• Aging...

Legislative push to boost preventive screening access:

• Rep. Cherfilus-McCormick (FL-20) introduces bill requiring private insurance, Medicare, and...

Lipid Management Advances

• 🔥 Oral PCSK9 Inhibitor Enlicitide: Phase 3 trial shows enlicitide achieved approximately 65% LDL-C reduction compared...

Oral PCSK9 inhibitor enlicitide achieved ~65% LDL-C reduction in Phase 3 trial vs ~37% for ezetimibe–bempedoic acid combo—suggesting substantially superior results with practice-changing potential for prevention.

Targeted shift in T2D: Mixed dyslipidemia requires non-HDL-C focus beyond LDL-C to capture atherogenic remnants.

• Statins cornerstone, but combo...

Key updates for preventive cardiology:

• HeartFlow sues Cleerly for misusing AI intellectual property in cardiac imaging
• Deep learning models enable...

Nearly 1 in 5 women develop hypertension within 7 years post-first pregnancy.

Key drivers:

• BMI ≥25 accounts for 41.5% of risk, strongest factor
  -...

New study of 28,000 GLP1 users reveals genetic keys to variable weight loss and side effects:

• GLP1R variant adds ~0.7kg loss per copy; GIPR ties to...

New EHRA 2026 post-hoc analysis of Swedish STROKESTOP trials urges action on smartwatch AF detection:

• Screen-detected AF in 75-76y olds led to...

Cholesterol Guideline Updates

• 🔥 Lower LDL Targets: American Heart Association and 10 other organizations recommend starting cholesterol checks...